PacBio to Report First Quarter 2026 Financial Results on May 7, 2026
PacBio and Covaris Announce Joint Workflow Enabling HiFi Long-Read Sequencing of FFPE Tumor Samples
Pacific Biosciences of California (PACB) had its price target lowered by Barclays PLC from $1.50 to $1.00. They now have an "underweight" rating on the stock.
Pacific Biosciences (PACB) Garnering Attention Amid Involvement in Trillion Gene Atlas Program [Yahoo! Finance]
Assembling Over 1,000 Human Genomes Affordably: New Method Powers Medicine's Future [Yahoo! Finance]